<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27791105</article-id>
<article-id pub-id-type="pmc">5098640</article-id>
<article-id pub-id-type="publisher-id">201608819</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1608819113</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Neuroscience</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function</article-title>
<alt-title alt-title-type="short">Brain network dynamics and risk of schizophrenia</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Braun</surname>
<given-names>Urs</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schäfer</surname>
<given-names>Axel</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-6183-4493</contrib-id>
<name>
<surname>Bassett</surname>
<given-names>Danielle S.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rausch</surname>
<given-names>Franziska</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schweiger</surname>
<given-names>Janina I.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bilek</surname>
<given-names>Edda</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Erk</surname>
<given-names>Susanne</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Romanczuk-Seiferth</surname>
<given-names>Nina</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grimm</surname>
<given-names>Oliver</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Geiger</surname>
<given-names>Lena S.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haddad</surname>
<given-names>Leila</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Otto</surname>
<given-names>Kristina</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mohnke</surname>
<given-names>Sebastian</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Heinz</surname>
<given-names>Andreas</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zink</surname>
<given-names>Mathias</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walter</surname>
<given-names>Henrik</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schwarz</surname>
<given-names>Emanuel</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meyer-Lindenberg</surname>
<given-names>Andreas</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tost</surname>
<given-names>Heike</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>2</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup>Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, <institution>University of Heidelberg</institution>, Mannheim, <country>Germany</country>;</aff>
<aff id="aff2"><sup>b</sup>Department of Bioengineering, <institution>University of Pennsylvania</institution>, Philadelphia, <addr-line>PA</addr-line> 19104;</aff>
<aff id="aff3"><sup>c</sup>Department of Electrical &amp; Systems Engineering, <institution>University of Pennsylvania</institution>, Philadelphia, <addr-line>PA</addr-line> 19104;</aff>
<aff id="aff4"><sup>d</sup>Department of Psychiatry and Psychotherapy, <institution>Charité–University Medicine Berlin</institution>, Campus Mitte, Berlin, <country>Germany</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>2</sup>To whom correspondence may be addressed. Email: <email>urs.braun@zi-mannheim.de</email> or <email>heike.tost@zi-mannheim.de</email>.</corresp>
<fn fn-type="edited-by">
<p>Edited by Edward T. Bullmore, University of Cambridge, Cambridge, United Kingdom, and accepted by Editorial Board Member Michael S. Gazzaniga September 6, 2016 (received for review June 1, 2016)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: U.B., A.S., D.S.B., F.R., S.E., N.R.-S., A.H., M.Z., H.W., A.M.-L., and H.T. designed research; U.B., A.S., F.R., J.I.S., E.B., S.E., N.R.-S., O.G., L.S.G., L.H., K.O., S.M., A.H., M.Z., H.W., A.M.-L., and H.T. performed research; U.B., D.S.B., E.S., and H.T. contributed new reagents/analytic tools; U.B., A.S., D.S.B., J.I.S., and E.S. analyzed data; and U.B., A.S., D.S.B., E.S., A.M.-L., and H.T. wrote the paper.</p>
</fn>
<fn fn-type="equal" id="fn1">
<p><sup>1</sup>U.B., A.S., and D.S.B. contributed equally to this work.</p>
</fn>
<fn fn-type="COI-statement">
<p>Conflict of interest statement: A.M.-L. received consultancy fees from Astra Zeneca, Elsevier, F. Hoffmann–La Roche, the Gerson Lehrman Group, The Lundbeck Foundation, Outcome Europe Sárl, Outcome Sciences, Roche Pharma, Servier International, and Thieme Verlag, and lecture fees, including the travel fees, from Abbott, Astra Zeneca, Aula Médica Congresos, Badische Anilin- &amp; Soda-Fabrik, Groupo Ferrer International, Janssen–Cilag, Lilly Deutschland, Landschaftsverband Rheinland Klinikum Düsseldorf, Servier Deutschland, and Otsuka Pharmaceuticals. M.Z. received scientific funding from Bristol–Myers Squibb and Servier; speaker and travel grants were provided from Pfizer Pharma GmbH, Bristol–Myers Squibb Pharmaceuticals, Otsuka, Servier, Lundbeck, Janssen–Cilag, Roche, Ferrer, and Trommsdorff.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>1</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>17</day>
<month>10</month>
<year>2016</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>113</volume>
<issue>44</issue>
<fpage>12568</fpage>
<lpage>12573</lpage>
<permissions>
<license license-type="open-access">
<license-p>Freely available online through the PNAS open access option.</license-p>
</license>
</permissions>
<self-uri xlink:href="pnas.201608819.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>Converging evidence points to a role for glutamate and altered brain network dynamics in schizophrenia, but the molecular and genetic contributions are poorly understood. Here, we applied dynamic network neuroscience methods to neuroimaging working memory data to identify potential alterations in brain network flexibility related to schizophrenia genetic risk and <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) receptor hypofunction. Consistent with altered network dynamics, we detected significant increases in brain network flexibility in patients with schizophrenia, healthy first-degree relatives, and healthy subjects receiving a single dose of an NMDA receptor antagonist. Our data identify a potential dynamic network intermediate phenotype related to the genetic risk for schizophrenia and point to a critical role for glutamate in the temporal coordination of neural networks and the pathophysiology of schizophrenia.</p>
</abstract>
<abstract>
<p>Schizophrenia is increasingly recognized as a disorder of distributed neural dynamics, but the molecular and genetic contributions are poorly understood. Recent work highlights a role for altered <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) receptor signaling and related impairments in the excitation–inhibitory balance and synchrony of large-scale neural networks. Here, we combined a pharmacological intervention with novel techniques from dynamic network neuroscience applied to functional magnetic resonance imaging (fMRI) to identify alterations in the dynamic reconfiguration of brain networks related to schizophrenia genetic risk and NMDA receptor hypofunction. We quantified “network flexibility,” a measure of the dynamic reconfiguration of the community structure of time-variant brain networks during working memory performance. Comparing 28 patients with schizophrenia, 37 unaffected first-degree relatives, and 139 healthy controls, we detected significant differences in network flexibility [<italic>F</italic>(2,196) = 6.541, <italic>P</italic> = 0.002] in a pattern consistent with the assumed genetic risk load of the groups (highest for patients, intermediate for relatives, and lowest for controls). In an observer-blinded, placebo-controlled, randomized, cross-over pharmacological challenge study in 37 healthy controls, we further detected a significant increase in network flexibility as a result of NMDA receptor antagonism with 120 mg dextromethorphan [<italic>F</italic>(1,34) = 5.291, <italic>P</italic> = 0.028]. Our results identify a potential dynamic network intermediate phenotype related to the genetic liability for schizophrenia that manifests as altered reconfiguration of brain networks during working memory. The phenotype appears to be influenced by NMDA receptor antagonism, consistent with a critical role for glutamate in the temporal coordination of neural networks and the pathophysiology of schizophrenia.</p>
</abstract>
<kwd-group>
<kwd>dynamic network neuroscience</kwd>
<kwd>schizophrenia</kwd>
<kwd>NMDA receptor function</kwd>
<kwd>intermediate phenotype</kwd>
<kwd>working memory</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)<named-content content-type="funder-id">501100002347</named-content></funding-source>
<award-id rid="sp1">01GQ1102</award-id>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">John D. and Catherine T. MacArthur Foundation<named-content content-type="funder-id">100000870</named-content></funding-source>
<award-id rid="sp2">n.a.</award-id>
</award-group>
<award-group id="gs3">
<funding-source id="sp3">Alfred P. Sloan Foundation (Sloan Foundation)<named-content content-type="funder-id">100000879</named-content></funding-source>
<award-id rid="sp3">n.a.</award-id>
</award-group>
<award-group id="gs4">
<funding-source id="sp4">DOD | Army Research Office (ARO)<named-content content-type="funder-id">100000183</named-content></funding-source>
<award-id rid="sp4">W911NF-10-2-0022 and W911NF-14-1-0679</award-id>
</award-group>
<award-group id="gs5">
<funding-source id="sp5">HHS | NIH | National Institute of Mental Health (NIMH)<named-content content-type="funder-id">100000025</named-content></funding-source>
<award-id rid="sp5">2-R01-DC-009209-11</award-id>
</award-group>
<award-group id="gs6">
<funding-source id="sp6">HHS | NIH | National Institute of Child Health and Human Development (NICHD)<named-content content-type="funder-id">100000071</named-content></funding-source>
<award-id rid="sp6">1R01HD086888-01</award-id>
</award-group>
<award-group id="gs7">
<funding-source id="sp7">DOD | Office of Naval Research (ONR)<named-content content-type="funder-id">100000006</named-content></funding-source>
<award-id rid="sp7">n.a.</award-id>
</award-group>
<award-group id="gs8">
<funding-source id="sp8">National Science Foundation (NSF)<named-content content-type="funder-id">100000001</named-content></funding-source>
<award-id rid="sp8">BCS-1441502 and BCS-1430087</award-id>
</award-group>
<award-group id="gs9">
<funding-source id="sp9">Deutsche Forschungsgemeinschaft (DFG)<named-content content-type="funder-id">501100001659</named-content></funding-source>
<award-id rid="sp9">SFB 636</award-id>
<award-id rid="sp9">subproject B7</award-id>
</award-group>
<award-group id="gs10">
<funding-source id="sp10">Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)<named-content content-type="funder-id">501100002347</named-content></funding-source>
<award-id rid="sp10">01ZX1314G</award-id>
</award-group>
<award-group id="gs11">
<funding-source id="sp11">Innovative Medicines Initiative Joint Undertaking (IMI)</funding-source>
<award-id rid="sp11">115300 and 602805</award-id>
</award-group>
<award-group id="gs12">
<funding-source id="sp12">Deutsche Forschungsgemeinschaft (DFG)<named-content content-type="funder-id">501100001659</named-content></funding-source>
<award-id rid="sp12">1253/3-1 and 1253/3-2</award-id>
</award-group>
<award-group id="gs13">
<funding-source id="sp13">Deutsche Forschungsgemeinschaft (DFG)<named-content content-type="funder-id">501100001659</named-content></funding-source>
<award-id rid="sp13">SCHW 1768/1-1</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="6"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>